## **LEGEND-T2DM Evidence Dissemination Summary**

Target: dapagliflozin, Comparator: glimepiride Outcome: Diarrhea Subgroup: All

## How Often? (Incidence Rates from Target in PS-matched cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	12,918	10,736	265	24.68
Clinformatics	4,649	2,289	82	35.82
DA Germany	4,586	3,518	9	2.56
LDP France	-	-	-	-
MDCD	982	465	21	45.15
MDCR	800	507	16	31.53
Open Claims	136,453	104,970	1,433	13.65
Optum EHR	9,317	2,116	61	28.83
Veterans Affairs	-	-	-	-

## How Reliable Are the Effect Estimates? (Objective Diagnostics from PS Matching) Comparator Target ■ Before ■ After MDRR Negative control Calibrated estimate EASE = 0.05 Equipoise = 0.70Max ASDM = 0.05MDRR = 1.20.89(0.72 - 1.09)CCAE Max ASDM = 0.07MDRR = 1.3 EASE = 0.05 0.73 (0.54 - 0.98) Equipoise = 0.25 Clinformatics Max ASDM = 0.12EASE = 0.12 • Equipoise = 0.36 MDRR = 6.3DA Germany LDP France Max ASDM = 0.140.58 (0.32 - 1.04) Equipoise = 0.41 MDRR = 1.6MDCD +Max ASDM = 0.15Equipoise = 0.38 MDRR = 1.8EASE = 0.080.70(0.36 - 1.36)**MDCR** +Max ASDM = 0.05MDRR = 1.1 0.87 (0.75 – 1.01) EASE = 0.07Equipoise = 0.55 Open Claims ₩ Max ASDM = 0.05EASE = 0.07 0.89(0.65 - 1.22)Equipoise = 0.53MDRR = 1.3Optum EHR Veterans Affairs 0.0 0.5 1.0 -0.5 0.0 0.5 0.5 0.5 2 10 Std. diff. means **MDRR** Preference score Hazard ratio Hazard ratio What have we learned from the OHDSI Network? (composite estimates) MDRR Negative control Estimate Calibrated estimate MDRR = 1.2EASE = 0.07 • $I^2 = 0$ 0.87 (0.70 - 1.08)Meta-analysis 10 0.5 **MDRR** Hazard ratio Hazard ratio Hazard ratio